2026-10-19T02:18:30Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/110822026-10-18T20:26:11Zopenairedrivercom_ebyu_10000col_ebyu_10001

Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5)Taşçı, Elif ŞenocakOyan, BaşakSönmez, ÖzlemMutlu, Arda UlaşAtcı, Muhammed MustafaSakin, AbdullahÖner, İremÇınkır, Havva YeşilEryılmaz, Melek KarakurtÇağlayan, DilekBalçık, Onur YazdanPaksoy, NailKarabulut, SenemSalim, Derya KıvrakBilir, CemilÖzen, MiraçÖzçelik, MelikeArıcan, AliAkagündüz, Baranİnal, AliAydın, DinçerÖzer, LeylaGülmez, AhmetTurhal, Nazım SerdarEsen, Selin AktürkAlgın, EfnanAkbaş, Sinemİriağaç, YakupŞakalar, TeomanÜnal, ÇağlarEr, ÖzlemSeçmeler, ŞabanBozkurt, Mustafafluorouracilregorafenibarticlecolon cancerdrug combinationmalignant neoplasmmetastatic colorectal cancertherapythird-line treatmentclinical articledrug therapyerratumhumanintravenous drug administrationmaleFollowing publication of the original article [1], the authors reported an error in the affiliations of authors Başak Oyan, Özlem Sönmez, Leyla Özer, Ali Arıcan, Özlem Er and Mustafa Bozkurt. These authors are all affiliated to institution 2. The original article [1] has been corrected. © 2024, The Author(s).BioMed Central Ltd2024Correctionhttps://rdlopen.rawdatalibrary.net/r/ebyu/11082https://doi.org/10.1186/s12885-024-11863-01471-2407enBMC Cancerinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/11082